Hims & Hers Health forecasted Q1 revenue between $600 million and $625 million, slightly below the Street's $616–650 million estimate, impacted by a $65 million GLP-1 headwind. The company expects GAAP EPS to fall about 83% year-over-year to roughly $0.03, signaling a margin reset already factored into current estimates. Despite this, short interest remains high at about 34% of the float, with 2–3 days to cover, suggesting potential for increased stock volatility. Valuation metrics stand at approximately 2.3 times 2026 sales and 53 times forward P/E, indicating the need for business stabilization and margin recovery to justify current prices.
Hims & Hers stock rebounded sharply from below $14 after regulatory challenges, now trading above $37 driven by robust monthly weight-loss subscriber additions exceeding 100,000. The company leverages GLP-1 products as a key customer acquisition tool...
The Amplify Online Retail ETF (IBUY) saw a significant rally in June, driven by strong performance in digital healthcare, specialized e-commerce, and online travel stocks. Key contributors included Hims & Hers Health, Wayfair, Tripadvisor, Instacart,...
